^
    Contact us  to learn more about
    our Premium Content:  News alerts, weekly reports and conference planners
    CANCER:

    Rectal Cancer

    Related cancers:
    19h
    Preoperative ChemoRadiation And FOLFOXIRI for Rectal Cancer (CRAFTER) for Rectal Cancer (clinicaltrials.gov)
    P2, N=38, Suspended, Rutgers, The State University of New Jersey | Trial completion date: Jan 2026 --> Jan 2028 | Recruiting --> Suspended | Trial primary completion date: Jan 2026 --> Dec 2027
    Trial completion date • Trial suspension • Trial primary completion date
    |
    CD4 (CD4 Molecule)
    |
    5-fluorouracil • capecitabine • oxaliplatin • irinotecan • leucovorin calcium
    1d
    Safety and Efficacy of Serplulimab Combined with Neoadjuvant Chemoradiotherapy in High-Risk Locally Advanced Rectal Cancer: A Retrospective Study. (PubMed, Cancer Manag Res)
    All enrolled patients received conventional radiotherapy combined with CapeOX or capecitabine monotherapy, along with serplulimab, followed by TME 8-12 weeks post-nCRT. The combination of serplulimab with nCRT demonstrated safety and efficacy in patients with high-risk pMMR LARC. However, further verification through longer follow-up periods and large-scale prospective studies is warranted.
    Retrospective data • Journal
    |
    MSI (Microsatellite instability)
    |
    MSI-H/dMMR
    |
    capecitabine • Hetronifly (serplulimab)
    1d
    Response-adapted Total Neoadjuvant Therapy Guided by Induction Chemotherapy in Early- and Intermediate-risk Low Rectal Cancer for Implementation of a Watch-and-wait Strategy (clinicaltrials.gov)
    P=N/A, N=60, Recruiting, West China Hospital
    New trial
    1d
    Modified Title Project 4: Effect of Meal Timing During Cancer Treatment in Alaska Native Patients (clinicaltrials.gov)
    P=N/A, N=100, Not yet recruiting, Fred Hutchinson Cancer Center | Initiation date: Aug 2025 --> Dec 2025
    Trial initiation date
    3d
    SHOOL: Short Course or Long Course Radiotherapy as Total Neoadjuvant Therapy in Locally Advanced Rectal Cancer (clinicaltrials.gov)
    P=N/A, N=150, Not yet recruiting, Rajiv Gandhi Cancer Institute & Research Center, India
    New trial
    |
    capecitabine • oxaliplatin • irinotecan
    3d
    Contribution of Preserving the Superior Left Colic Artery to the Vascularization of the Descending Colon Prior to Colorectal Anastomosis During Left-Sided or Rectal Resections for Colorectal or Ovarian Cancer. (Revascularisation Colique) (clinicaltrials.gov)
    P=N/A, N=50, Recruiting, Institut du Cancer de Montpellier - Val d'Aurelle | Not yet recruiting --> Recruiting
    Enrollment open
    3d
    Predictive value of tumor marker index for pathological complete response following neoadjuvant chemoradiotherapy in locally advanced rectal cancer. (PubMed, World J Surg Oncol)
    Pre-treatment TMI is an independent predictor of pCR and correlates with lower recurrence in LARC after nCRT. Given its high sensitivity/NPV at the identified threshold, TMI may support organ-preservation discussions and guide treatment intensification strategies; prospective validation is warranted.
    Journal
    |
    CA 19-9 (Cancer antigen 19-9)
    4d
    SCRT-CAPEOX-Serplulimab for MSS/pMMR Rectal Cancer With Oligometastases (clinicaltrials.gov)
    P2, N=102, Recruiting, First Affiliated Hospital of Zhejiang University | Not yet recruiting --> Recruiting
    Enrollment open • Mismatch repair • pMMR
    |
    capecitabine • oxaliplatin • Hetronifly (serplulimab)
    4d
    Paracrine iron activates Hopx+ rectal cancer stem cells to display radioresistance. (PubMed, J Adv Res)
    Collectively, quiescent cancer stem cells could establish a new dependency on anti-apoptotic programs in their dying neighbors. This study highlights targeting and regulating Hopx+ quiescent stem cells could be a promising therapeutic approach to overcome the refractoriness of human rectal cancer.
    Journal
    |
    STAT3 (Signal Transducer And Activator Of Transcription 3)
    4d
    Neoadjuvant immunotherapy for dMMR/MSI-H locally advanced rectal cancer patients: demystifying the 100% clinical complete response paradigm. (PubMed, Oncologist)
    shows a cCR rate of 100% that allowed sparing chemoradiation and surgery to all included patients. Here, we present three clinical cases of patients with dMMR and MSI-H LARC treated with neoadjuvant dostarlimab at three Italian institutions with radiological evidence of disease progression while on treatment and discuss potential similarities among them to understand when and how this apparently rare event may occur.
    Journal • MSI-H • dMMR
    |
    MSI (Microsatellite instability)
    |
    MSI-H/dMMR
    |
    Jemperli (dostarlimab-gxly)
    7d
    BFT in LARS: The Effects of Kegel Exercise Combined With Biofeedback Therapy on Bowel Function Recovery, Emotional Distress, and Quality of Life in Patients Following Low Anterior Resection for Rectal Cancer (clinicaltrials.gov)
    P=N/A, N=66, Not yet recruiting, National Taiwan University Hospital
    New trial • HEOR
    7d
    Acid ceramidase expression and biomarker potential in patients with locally advanced rectal cancer. (PubMed, Biomol Biomed)
    A key finding of this study is the inverse relationship between serum AC levels and the pro-apoptotic status of tumor tissue, suggesting that circulating AC may provide valuable insights into tumor apoptotic activity. Further large-scale studies are necessary to validate these preliminary findings and elucidate the biomarker potential of AC in rectal cancer.
    Journal • IO biomarker
    |
    BCL2 (B-cell CLL/lymphoma 2) • BAX (BCL2-associated X protein)